Cromos Pharma, where the patients are


Lieber Institute forms consortium to develop brain disorder treatments

Wednesday, April 9, 2014 12:31 PM

The Lieber Institute for Brain Development (LIBD), an independent nonprofit, and pharmaceutical companies Astellas, Eli Lilly, Lundbeck, Pfizer and Roche are participating in an early-stage research consortium to analyze RNA, the genomic and epigenetic data obtained from human brains. The goal of the consortium is to expand knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.

More... »

CRF Health eCOA webinar series

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

Otsuka, Lundbeck partner in Japan

Friday, November 1, 2013 11:16 AM

H. Lundbeck and Otsuka Pharmaceutical said their existing alliance now also includes development and commercialization of nalmefene (sold under the brand name Selincro in Europe) in Japan. Earlier this year, nalmefene was approved by the EMA as the first treatment for the reduction of alcohol consumption.

More... »

MJFF donates $1 million for two Lundbeck research projects

Wednesday, October 16, 2013 10:26 AM

Danish pharmaceutical company Lundbeck has been awarded two research grants totaling $1 million from The Michael J. Fox Foundation (MJFF) for Parkinson's research.  

More... »

Lundbeck simplifies and restructures, 200 jobs to be cut

Monday, September 30, 2013 03:40 PM

Lundbeck, a global pharmaceutical company specialized in brain diseases, has simplified its commercial structure, increased alignment across countries and improved competencies and investments in market access as a result of its Fit-for-the-Future program.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Lundbeck to simplify commercial structure

Friday, June 21, 2013 01:30 PM

Global pharmaceutical Lundbeck has plans to optimize its commercial structure in order to launch new medicines, through increased alignment across countries and improved competencies and investments in areas such as market access.   

More... »

Lundbeck, Otsuka expand alliance, plan to development Lu AE58054 for Alzheimer's

Wednesday, March 27, 2013 11:24 AM

Global pharmaceutical company H. Lundbeck and global healthcare company Otsuka Pharmaceutical have formed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Recordati finalizes acquisition of portfolio from Lundbeck

Wednesday, January 23, 2013 11:25 AM

Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs